Optimizing hypertension care in the real world: a physician survey on telmisartan‑based combination therapy
DOI:
https://doi.org/10.18203/2320-6012.ijrms20261849Keywords:
Hypertension, Telmisartan, Combination therapy, Blood pressure control, Physician survey, Cardiovascular riskAbstract
Background: Hypertension is a leading cause of global cardiovascular morbidity and mortality and most patients require combination therapy to achieve recommended blood pressure targets and reduce cardiovascular risk.
Methods: This cross-sectional, questionnaire-based survey was conducted among 98 physicians attending a scientific meeting organized by the Cardiological society of India (CSI). The survey evaluated real-world hypertension management, including BP targets, use of combination therapy, preferred drug combinations and factors influencing telmisartan selection.
Results: Most physicians reported frequent use of combination therapy at the time of treatment initiation, with 46% indicating its use in 20-40% of patients and 38% in 40-60% of patients. Blood pressure targets varied, with nearly half of respondents (48%) aiming for <130/80 mm Hg, while 30% targeted <140/90 mm Hg. Telmisartan plus amlodipine emerged as the most preferred first‑line combination (48%), followed by telmisartan plus chlorthalidone (31%). The telmisartan–amlodipine combination was commonly selected for patients with uncontrolled blood pressure (44%) and those presenting with stage 2 hypertension (41%). Triple therapy with telmisartan, cilnidipine, and chlorthalidone was predominantly reserved for resistant hypertension (57%). Regression of left ventricular hypertrophy (31%) and the presence of microalbuminuria (29%) were key factors influencing preference for telmisartan.
Conclusions: The survey highlights a growing preference among clinicians for early combination therapy, intensive BP targets and therapies providing sustained 24-hour BP control. Telmisartan-based combinations were widely preferred, reflecting their complementary mechanisms and cardio-renal protective benefits. These findings suggest increasing adoption of guideline-directed strategies in real-world hypertension management.
References
Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-37. DOI: https://doi.org/10.1038/s41581-019-0244-2
Jones DW, Ferdinand KC, Taler SJ, Carey RM, Whelton PK, Wright JT, et al. 2025 AHA/ACC guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2025.
Gupta R, Gaur K, Ram CVS. Emerging trends in hypertension epidemiology in India. J Hum Hypertens. 2019;33(8):575-87. DOI: https://doi.org/10.1038/s41371-018-0117-3
Varghese JS, Venkateshmurthy NS, Sudharsanan N, Jeemon P, Patel SA, Thirumurthy H, et al. Hypertension Diagnosis, Treatment, and Control in India. JAMA Netw Open. 2023;6(10):e2339098. DOI: https://doi.org/10.1001/jamanetworkopen.2023.39098
Guerrero-García C, Rubio-Guerra AF. Combination therapy in the treatment of hypertension. Drugs Context. 2018;7:212531. DOI: https://doi.org/10.7573/dic.212531
Epstein BJ. Improving blood pressure control rates by optimizing combination antihypertensive therapy. Expert Opin Pharmacother. 2010;11(12):2011-26. DOI: https://doi.org/10.1517/14656566.2010.500614
Rosas-Peralta M, Mancia G, Camafort M, Galván-Oseguera H, Ferrario CM, Alcocer L, et al. Single pill combination therapy for hypertension: new evidence and new challenges: combination therapy for hypertension. Trends Cardiovasc Med. 2025;35(8):497-503. DOI: https://doi.org/10.1016/j.tcm.2025.06.004
Rajadhyaksha GC, Reddy H, Singh AK, Oomman A, Adhyapak SM. The Indian registry on current patient profiles and treatment trends in hypertension (RECORD): One year interim analysis. Indian J Med Res. 2023;158(3):244-55. DOI: https://doi.org/10.4103/ijmr.ijmr_3096_21
Thomopoulos C, Bazoukis G, Grassi G, Tsioufis C, Mancia G. Monotherapy vs combination treatments of different complexity: a meta-analysis of blood pressure lowering randomized outcome trials. J Hypertens. 2021;39(5):846-55. DOI: https://doi.org/10.1097/HJH.0000000000002759
Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874-2071. DOI: https://doi.org/10.1097/HJH.0000000000003480
King JB, An J, Bellows BK, Cohen JB, Commodore-Mensah Y, Ghazi L, et al; American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Single-Pill Combination Therapy for the Management of Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2026;83(3):e00258. DOI: https://doi.org/10.1161/HYP.0000000000000258
Ariwala P, Alexander W, Kapardhi P, Prasad A, Mishra S, Jain N, et al. A contemporary review on combination therapy for hypertension management in India. Int J Adv Med. 2026;13(1):150-6. DOI: https://doi.org/10.18203/2349-3933.ijam20261093
Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290-300. DOI: https://doi.org/10.1016/j.amjmed.2008.09.038
Wang N, Rueter P, Atkins E, Webster R, Huffman M, De Silva A, et.al. Efficacy and Safety of Low-Dose Triple and Quadruple Combination Pills vs Monotherapy, Usual Care, or Placebo for the Initial Management of Hypertension: A Systematic Review and Meta-analysis. JAMA Cardiol. 2023;8(6):606-11. DOI: https://doi.org/10.1001/jamacardio.2023.0720
Mishra HN, Shetty S, Chopra A, Sharma SK, Gupta R, Patel A, et al. Management of Hypertension and Associated Comorbidities: An Expert Consensus Statement from India. J Assoc Physicians India. 2025;73(9):e48-59. DOI: https://doi.org/10.59556/japi.73.1094
Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents. Hypertension. 2010;55(2):399-407. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.109.139816
Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA. 1996; 275:1507-13. DOI: https://doi.org/10.1001/jama.1996.03530430051039
Nath B, Dorairaj P, Nair T, Aurora A, Sengupta S, Sharma UP. Hypertension-mediated Organ Damage Care in India Go-Real (Guidelines tOReal World) Application: Expert Opinion. J Assoc Physicians India. 2025;73(3):e7-21. DOI: https://doi.org/10.59556/japi.73.0877
Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C. Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population-based study. Am J Hypertens. 2006;19(3):243-50. DOI: https://doi.org/10.1016/j.amjhyper.2005.09.018
Hermida RC, Crespo JJ, Domínguez-Sardiña M, Otero A, Moyá A, Ríos MT, et al. Hygia Project Investigators. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. 2020;41(48):4565-76. DOI: https://doi.org/10.1093/eurheartj/ehz754
Downloads
Published
How to Cite
Issue
Section
